ArticleBMC cancer2024

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.

Tae-Hwan Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.